Search

Displaying results 6581 - 6590 of 7379 in total
  1. Drug

    Asapiprant

    go.drugbank.com/drugs/DB20492
    Investigational

    Asapiprant is under investigation in clinical trial NCT04705597 (Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That

  2. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.

  3. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).

  4. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]

  5. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S)

  6. Drug

    Cenacitinib

    go.drugbank.com/drugs/DB21735
    Investigational

    Cenacitinib is under investigation in clinical trial NCT05688852 (VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease).

  7. Drug

    Oxprenolol

    go.drugbank.com/drugs/DB01580
    ApprovedWithdrawn

    A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

  8. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  9. Drug

    7MW3711

    go.drugbank.com/drugs/DB19298
    Investigational

    Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]

  10. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]